Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Operating Expenses (2018 - 2025)

Historic Operating Expenses for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to $19.5 million.

  • Whitehawk Therapeutics' Operating Expenses fell 523.15% to $19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $122.8 million, marking a year-over-year increase of 3456.23%. This contributed to the annual value of $93.4 million for FY2024, which is 295.57% down from last year.
  • Latest data reveals that Whitehawk Therapeutics reported Operating Expenses of $19.5 million as of Q3 2025, which was down 523.15% from $54.7 million recorded in Q2 2025.
  • Whitehawk Therapeutics' Operating Expenses' 5-year high stood at $87.3 million during Q3 2021, with a 5-year trough of $3.9 million in Q2 2021.
  • Moreover, its 5-year median value for Operating Expenses was $21.8 million (2022), whereas its average is $25.1 million.
  • As far as peak fluctuations go, Whitehawk Therapeutics' Operating Expenses soared by 291696.61% in 2021, and later crashed by 7791.69% in 2022.
  • Over the past 5 years, Whitehawk Therapeutics' Operating Expenses (Quarter) stood at $16.9 million in 2021, then rose by 22.15% to $20.7 million in 2022, then rose by 16.14% to $24.0 million in 2023, then grew by 8.94% to $26.2 million in 2024, then decreased by 25.36% to $19.5 million in 2025.
  • Its Operating Expenses stands at $19.5 million for Q3 2025, versus $54.7 million for Q2 2025 and $22.4 million for Q1 2025.